Logo
x

Search

Subscribe Now

Daiichi Sankyo

Daiichi Sankyo Reports the MHLW’s Approval of Ezharmia (Valemetostat Tosilate) To Treat Peripheral T-Cell Lymphoma

Daiichi Sankyo Reports the MHLW’s Approval of Ezharmia (Valemetostat Tosilate) To Treat Peripheral T-Cell Lymphoma

  • June 25, 2024
PharmaShots Weekly Snapshots (April 29 – May 03, 2024)

PharmaShots Weekly Snapshots (April 29 – May 03, 2024)

  • May 3, 2024
Daiichi Sankyo and AstraZeneca Report the P-III (DESTINY-Breast06) Study Data of Enhertu to Treat Breast Cancer

Daiichi Sankyo and AstraZeneca Report the P-III (DESTINY-Breast06) Study Data of Enhertu to Treat Breast Cancer

  • April 29, 2024
PharmaShots Weekly Snapshots (March 11 – March 15, 2024)

PharmaShots Weekly Snapshots (March 11 – March 15, 2024)

  • March 15, 2024
Daiichi Sankyo Submits NDA of Datopotamab Deruxtecan to the MHLW for the Treatment of Advanced Breast Cancer

Daiichi Sankyo Submits NDA of Datopotamab Deruxtecan to the MHLW for the Treatment of Advanced Breast Cancer

  • March 14, 2024
Daiichi Sankyo and AstraZeneca Reports the US FDA’s Acceptance of BLA for Datopotamab Deruxtecan (Dato-DXd) to Treat Non-Small Cell Lung Cancer

Daiichi Sankyo and AstraZeneca Reports the US FDA’s Acceptance of BLA for Datopotamab Deruxtecan (Dato-DXd) to Treat Non-Small Cel...

  • February 19, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.